Literature DB >> 9667969

Tripeptide aldehyde inhibitors of human rhinovirus 3C protease: design, synthesis, biological evaluation, and cocrystal structure solution of P1 glutamine isosteric replacements.

S E Webber1, K Okano, T L Little, S H Reich, Y Xin, S A Fuhrman, D A Matthews, R A Love, T F Hendrickson, A K Patick, J W Meador, R A Ferre, E L Brown, C E Ford, S L Binford, S T Worland.   

Abstract

The investigation of tripeptide aldehydes as reversible covalent inhibitors of human rhinovirus (HRV) 3C protease (3CP) is reported. Molecular models based on the apo crystal structure of HRV-14 3CP and other trypsin-like serine proteases were constructed to approximate the binding of peptide substrates, generate transition state models of P1-P1' amide cleavage, and propose novel tripeptide aldehydes. Glutaminal derivatives have limitations since they exist predominantly in the cyclic hemiaminal form. Therefore, several isosteric replacements for the P1 carboxamide side chain were designed and incorporated into the tripeptide aldehydes. These compounds were found to be potent inhibitors of purified HRV-14 3CP with Kis ranging from 0.005 to 0.64 microM. Several have low micromolar antiviral activity when tested against HRV-14-infected H1-HeLa cells. The N-acetyl derivative 3 was also shown to be active against HRV serotypes 2, 16, and 89. High-resolution cocrystal structures of HRV-2 3CP, covalently bound to compounds 3, 15, and 16, were solved. These cocrystal structures were analyzed and compared with our original HRV-14 3CP-substrate and inhibitor models.

Entities:  

Mesh:

Substances:

Year:  1998        PMID: 9667969     DOI: 10.1021/jm980071x

Source DB:  PubMed          Journal:  J Med Chem        ISSN: 0022-2623            Impact factor:   7.446


  33 in total

1.  Structure-assisted design of mechanism-based irreversible inhibitors of human rhinovirus 3C protease with potent antiviral activity against multiple rhinovirus serotypes.

Authors:  D A Matthews; P S Dragovich; S E Webber; S A Fuhrman; A K Patick; L S Zalman; T F Hendrickson; R A Love; T J Prins; J T Marakovits; R Zhou; J Tikhe; C E Ford; J W Meador; R A Ferre; E L Brown; S L Binford; M A Brothers; D M DeLisle; S T Worland
Journal:  Proc Natl Acad Sci U S A       Date:  1999-09-28       Impact factor: 11.205

2.  Prostate-specific antigen is a "chymotrypsin-like" serine protease with unique P1 substrate specificity.

Authors:  Aaron M LeBeau; Pratap Singh; John T Isaacs; Samuel R Denmeade
Journal:  Biochemistry       Date:  2009-04-21       Impact factor: 3.162

Review 3.  Protease inhibitors as antiviral agents.

Authors:  A K Patick; K E Potts
Journal:  Clin Microbiol Rev       Date:  1998-10       Impact factor: 26.132

4.  Inhibition of human rhinovirus-induced cytokine production by AG7088, a human rhinovirus 3C protease inhibitor.

Authors:  L S Zalman; M A Brothers; P S Dragovich; R Zhou; T J Prins; S T Worland; A K Patick
Journal:  Antimicrob Agents Chemother       Date:  2000-05       Impact factor: 5.191

5.  In vitro antiviral activity of AG7088, a potent inhibitor of human rhinovirus 3C protease.

Authors:  A K Patick; S L Binford; M A Brothers; R L Jackson; C E Ford; M D Diem; F Maldonado; P S Dragovich; R Zhou; T J Prins; S A Fuhrman; J W Meador; L S Zalman; D A Matthews; S T Worland
Journal:  Antimicrob Agents Chemother       Date:  1999-10       Impact factor: 5.191

6.  Structure-guided design, synthesis and evaluation of oxazolidinone-based inhibitors of norovirus 3CL protease.

Authors:  Vishnu C Damalanka; Yunjeong Kim; Anushka C Galasiti Kankanamalage; Athri D Rathnayake; Nurjahan Mehzabeen; Kevin P Battaile; Scott Lovell; Harry Nhat Nguyen; Gerald H Lushington; Kyeong-Ok Chang; William C Groutas
Journal:  Eur J Med Chem       Date:  2017-12-06       Impact factor: 6.514

7.  Design, synthesis, and evaluation of inhibitors of Norwalk virus 3C protease.

Authors:  Kok-Chuan Tiew; Guijia He; Sridhar Aravapalli; Sivakoteswara Rao Mandadapu; Mallikarjuna Reddy Gunnam; Kevin R Alliston; Gerald H Lushington; Yunjeong Kim; Kyeong-Ok Chang; William C Groutas
Journal:  Bioorg Med Chem Lett       Date:  2011-07-14       Impact factor: 2.823

8.  Structure-guided design and optimization of dipeptidyl inhibitors of norovirus 3CL protease. Structure-activity relationships and biochemical, X-ray crystallographic, cell-based, and in vivo studies.

Authors:  Anushka C Galasiti Kankanamalage; Yunjeong Kim; Pathum M Weerawarna; Roxanne Adeline Z Uy; Vishnu C Damalanka; Sivakoteswara Rao Mandadapu; Kevin R Alliston; Nurjahan Mehzabeen; Kevin P Battaile; Scott Lovell; Kyeong-Ok Chang; William C Groutas
Journal:  J Med Chem       Date:  2015-03-19       Impact factor: 7.446

9.  Discovery of Ketone-Based Covalent Inhibitors of Coronavirus 3CL Proteases for the Potential Therapeutic Treatment of COVID-19.

Authors:  Robert L Hoffman; Robert S Kania; Mary A Brothers; Jay F Davies; Rose A Ferre; Ketan S Gajiwala; Mingying He; Robert J Hogan; Kirk Kozminski; Lilian Y Li; Jonathan W Lockner; Jihong Lou; Michelle T Marra; Lennert J Mitchell; Brion W Murray; James A Nieman; Stephen Noell; Simon P Planken; Thomas Rowe; Kevin Ryan; George J Smith; James E Solowiej; Claire M Steppan; Barbara Taggart
Journal:  J Med Chem       Date:  2020-10-15       Impact factor: 7.446

10.  Potent and selective peptidyl boronic acid inhibitors of the serine protease prostate-specific antigen.

Authors:  Aaron M LeBeau; Pratap Singh; John T Isaacs; Samuel R Denmeade
Journal:  Chem Biol       Date:  2008-07-21
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.